VPC NeuroTherapeutics Inc.
Biopharmaceutical start-up (founded 2021, Hamilton ON) developing an oral small-molecule therapy to inhibit a prolonged macrophage-driven inflammatory disease of the central nervous system that follows neurotrauma (spinal cord injury, TBI, concussion) and stroke. The organization has >35 years of preclinical research in validated rat models, peer-reviewed publications, patent filings, early clinical evidence from a small acute SCI study, and active regulatory development (Health Canada testing program and a Pre-IND file with FDA).
Industries
N/A
Nr. of Employees
small (1-50)
VPC NeuroTherapeutics Inc.
Products
Oral anti-neuroinflammatory formulation (xanthohumol-based)
An oral small-molecule formulation containing a hop-derived flavonoid that reduces macrophage-driven inflammation, preserves peri-lesional CNS tissue, and eliminates vasogenic edema in preclinical models; being developed for acute SCI and later for TBI, concussion and stroke.
Oral anti-neuroinflammatory formulation (xanthohumol-based)
An oral small-molecule formulation containing a hop-derived flavonoid that reduces macrophage-driven inflammation, preserves peri-lesional CNS tissue, and eliminates vasogenic edema in preclinical models; being developed for acute SCI and later for TBI, concussion and stroke.
Services
Engagements for licensing intellectual property and collaborating on development and commercialization of neuroprotective therapies and related supplements.
Provision of expertise in validated rat models of spinal cord injury, experimental design, surgical models, dosing regimens, and data integration for neurotrauma studies.
Engagements for licensing intellectual property and collaborating on development and commercialization of neuroprotective therapies and related supplements.
Provision of expertise in validated rat models of spinal cord injury, experimental design, surgical models, dosing regimens, and data integration for neurotrauma studies.
Expertise Areas
- Neurotrauma pathogenesis research
- Preclinical pharmacology and animal model development
- Early-phase clinical study execution (acute SCI)
- Regulatory strategy and submissions (Pre-IND, PCT)
Key Technologies
- Rat spinal cord injury models
- Oral small-molecule therapeutics
- Blood-brain barrier penetration assessment
- Dose translation from animal to human
News & Updates
Presentation titled 'A Grain Protein with Anti-Neuroinflammatory Activity for Better Function in Aging Brain' delivered by company lead investigator.
U.S. patent issued covering treatment of inflammation initiated by spinal cord injury, traumatic brain injury and stroke (patent number referenced on site).
Manuscript on anti-inflammatory effect of rice protein in the rat SCI model made available as a preprint.
Presentation titled 'A Grain Protein with Anti-Neuroinflammatory Activity for Better Function in Aging Brain' delivered by company lead investigator.
U.S. patent issued covering treatment of inflammation initiated by spinal cord injury, traumatic brain injury and stroke (patent number referenced on site).
Manuscript on anti-inflammatory effect of rice protein in the rat SCI model made available as a preprint.